Clinical trial Recruiting at 1 site Observational Ages 18 to 90

How OR6A2 and octanal on monocytes relate to outcomes after myocardial ischemia-reperfusion injury

Official title: Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury

Run by Southeast University, China · NCT07100457 · Data updated 2026-11-12

This project tries to see if the OR6A2 receptor on monocytes and blood levels of octanal are linked to inflammation and later heart complications in people who had myocardial ischemia-reperfusion injury after PCI.

More Ischemia Reperfusion Injury trials

Quick facts

Study typeObservational
Ages18 Years to 90 Years
SexAll
Enrollment200 (estimated)
SponsorSoutheast University, China
Academic / other
Locations1 site (Nanjing, Jiangsu)
StatusRecruiting
StartedSeptember 1, 2019
Main results expectedAugust 30, 2027
Study endsAugust 30, 2027
Registry record updatedAugust 3, 2025
Trial IDNCT07100457 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults (age 18–90) with angiographically confirmed coronary artery disease who had an acute myocardial infarction treated with primary PCI and were diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.

Probably not a fit

Patients with active systemic infections, advanced heart failure (NYHA class III–IV), acute cerebrovascular events, myocarditis, cardiomyopathy, refractory ventricular arrhythmias, recent malignancy treatment, severe renal failure (eGFR <30 or dialysis), or Child-Pugh class C liver disease are excluded and unlikely to receive benefit from participation.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational study of patients who experienced myocardial ischemia-reperfusion injury after primary percutaneous coronary intervention. Investigators measure OR6A2 expression on monocyte subtypes, plasma octanal, and systemic oxidative stress and inflammatory biomarkers from blood samples taken after revascularization. They then correlate these molecular profiles with major adverse cardiovascular events identified during a 44-month clinical follow-up. The goal is to identify biomarker patterns that predict clinical outcomes and could support personalized risk stratification after revascularization.

Why it matters

Potential benefit: If successful, the findings could identify blood biomarkers that help predict which patients are at higher risk for complications after revascularization and guide more personalized follow-up or treatment.

How similar studies have gone: This line of inquiry is relatively novel—olfactory receptor signaling on immune cells like OR6A2 is an emerging area with limited direct clinical data, although biomarker correlations with inflammation and outcomes after reperfusion have been reported in related work.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
2. Age 18-90 years inclusive.

Exclusion Criteria:

1. Active systemic infections.
2. Advanced heart failure (NYHA class III-IV).
3. Acute cerebrovascular conditions.
4. Active myocarditis.
5. cardiomyopathy.
6. Refractory ventricular tachycardia/fibrillation.
7. Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ).
8. Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] \<30 mL/min/1.73m2 or dialysis dependence).
9. Child-Pugh class C hepatic dysfunction.

Where it's running

  • Department of Cardiology, Zhongda Hospital, Southeast University
    Nanjing, Jiangsu, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.